Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system. At the company’s Investor Day event, held at its Acton, Massachusetts headquarters, President and CEO Ashley McEvoy laid out the company’s innovation roadmap. That includes updates to the current-generation Omnipod 5 platform, the new Omnipod 6 and a new, […]
Insulet
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Insulet leadership talks patch pump competition, expanding type 2 diabetes market
As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries could be on the way. The Acton, Massachusetts–based company’s Omnipod platform has long been the leader in the patch pump space, with the latest-generation Omnipod 5 delivering nearly $700 million in revenue in the company’s recently announced […]
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
Insulet launches inclusion campaign for Diabetes Awareness Month
Insulet (Nasdaq:PODD) today announced a new Diabetes Awareness Month campaign called “The Day Diabetes Showed Up to Work.” The American Diabetes Association (ADA) Diabetes Awareness Month begins on Nov. 1. World Diabetes Day is also coming up on Nov. 14, marking the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles […]
Insulet adds JPMorgan veteran to its board of directors
Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]
Ashley McEvoy explains how Insulet is using AI to advance diabetes care
While Ashley McEvoy has only been at the helm of Insulet (Nasdaq:PODD) for five months, she’s already seeing the increasing role of AI in the company’s technology. Speaking during a “CEOs Unplugged” session covering the emergence of AI in medical technology at AdvaMed’s The MedTech Conference in San Diego alongside Stryker CEO Kevin Lobo and […]
Insulet makes CFO change, appoints longtime J&J leader
Insulet (Nasdaq:PODD) announced today that it appointed Flavia Pease to succeed Ana Maria Chadwick as EVP and CFO. The transition goes into effect on Sept. 30, 2025, Chadwick intends to become a senior advisor to Insulet to ensure a smooth transition. “I want to personally thank Ana, who has provided steady and thoughtful leadership for […]
Insulet eyes Middle East expansion as McEvoy talks future plans
Insulet (Nasdaq:PODD) has its eyes on future expansion in new geographies, according to some of its leading executives. Speaking during the Wells Fargo Conference last week (transcribed by Investing.com), President and CEO Ashley McEvoy and EVP and CFO Ana Maria Chadwick outlined expansion plans for its automated insulin delivery technology, particularly in the Middle East. […]
Insulet promotes from within to fill CTO role
Insulet (Nasdaq:PODD) announced today that it appointed Amit Guliani as its chief technology officer (CTO). Guliani’s appointment follows a nearly six-month tenure as acting CTO at the Acton, Massachusetts-based insulin pump maker. He took over in the interim role after Mark Field announced his departure in March. Previously, Guliani served as group VP, software engineering. […]
